Home > Insider Trading > Filing (0001209191-10-044632)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
352747	Unigene Laboratories Inc	UGNE	Medicinal Chemicals & Botanical Products (2833)	222328609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1413810	N Richard Levy	C/O Victory Park Capital Advisors, Llc 227 West Monroe Street, Suite 3900 Chicago IL 60606		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-08-27	176,633	$0.65	8,822,447	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2010-08-30	18,917	$0.68	8,841,364	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2010-08-31	50,000	$0.70	8,891,364	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions (all on August 27, 2010) at prices ranging from $0.61 to $0.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the reported securities are beneficially owned directly by Victory Park Credit Opportunities Master Fund, Ltd. (the "Fund") and indirectly by (i) Victory Park Capital Advisors, LLC as the investment manager for the Fund, (ii) Jacob Capital, L.L.C., as the manager of Victory Park Capital Advisors, LLC, and (iii) Richard Levy, as the sole member of Jacob Capital, L.L.C. Richard Levy disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions (all on August 30, 2010) at prices ranging from $0.65 to $0.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.